



coordinated care™

Hematopoietic Agents: Sickle Cell Anemia (Adakveo)

WA.PHAR.82 Hematopoietic Agents- Sickle Cell Anemia (Adakveo)

Effective Date: July 1, 2020

Background:

Crizanlizumab-tmca (Adakveo®) is a selectin blocker managed and paid by the Health Care Authority for Medicaid members.

All requests for authorization or payment must be referred to the Health Care Authority.

Coding:

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Code	Description
C9053	INJECTION CRIZANLIZUMAB-TMCA 1 MG
J0791	INJECTION CRIZANLIZUMAB-TMCA 5 MG

History

Date	Action and Summary of Changes
06/24/2020	<ul style="list-style-type: none">New Policy Created